US refiling an important step forward for Eisai's novel epilepsy drug perampanel
This article was originally published in Scrip
Executive Summary
Eisai has resubmitted a US new drug application for its innovative epilepsy drug perampanel, for which it is seeking approval in this key market as an adjunctive therapy for partial onset seizures associated with the disorder.